PD-1 INHIBITION CAN BE COMBINED WITH IL-12 IN SUBJECTS WITH RECURRENT GLIOBLASTOMA

被引：0
|
作者：
Chiocca, Ennio [1 ]
Lukas, Rimas [2 ]
Rao, Ganesh [3 ]
Buck, Jill [4 ]
Demars, Nathan [4 ]
Smith, Amy [4 ]
Miao, John [4 ]
Zhou, John [4 ]
Gelb, Arnold [4 ]
Cooper, Laurence [4 ]
机构：
[1] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA
[2] Northwestern Med, Chicago, IL USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Ziopharm Oncol Inc, Boston, MA USA
来源：
NEURO-ONCOLOGY | 2019年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ATIM-25
引用
收藏
页码：6 / 7
页数：2
相关论文
共 50 条
  • [31] Prognostic factors and outcomes in metastatic uveal melanoma treated with PD-1 or combined PD-1 / CTLA-4 inhibition
    Heppt, M.
    Heinzerling, L.
    Kaehler, K.
    Forschner, A.
    Kirchberger, M.
    Loquai, C.
    Meissner, M.
    Meier, F.
    Terheyden, P.
    Schell, B.
    Herbst, R.
    Goeppner, D.
    Kiecker, F.
    Rafei-Shamsabadi, D.
    Haferkamp, S.
    Huber, M.
    Utikal, J.
    Ziemer, M.
    Bumeder, I
    Pfeiffer, C.
    Schd-Trcka, S.
    Schmid-Tannwald, C.
    Tietze, J.
    Eigentler, T.
    Berking, C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 : 14 - 14
  • [32] Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF
    Di Tacchio, Mariangela
    Macas, Jadranka
    Weissenberger, Jakob
    Sommer, Kathleen
    Baehr, Oliver
    Steinbach, Joachim P.
    Senft, Christian
    Seifert, Volker
    Glas, Martin
    Herrlinger, Ulrich
    Krex, Dietmar
    Meinhardt, Matthias
    Weyerbrock, Astrid
    Timmer, Marco
    Goldbrunner, Roland
    Deckert, Martina
    Scheel, Andreas H.
    Buettner, Reinhard
    Grauer, Oliver M.
    Schittenhelm, Jens
    Tabatabai, Ghazaleh
    Harter, Patrick N.
    Guenther, Stefan
    Devraj, Kavi
    Plate, Karl H.
    Reiss, Yvonne
    CANCER IMMUNOLOGY RESEARCH, 2019, 7 (12) : 1910 - 1927
  • [33] Enhanced therapeutic efficacy for glioblastoma immunotherapy with an oncolytic herpes simplex virus armed with anti-PD-1 antibody and IL-12
    Wang, Lei
    Zhou, Xusha
    Chen, Xiaoqing
    Liu, Yuanyuan
    Huang, Yue
    Cheng, Yuan
    Ren, Peigen
    Zhao, Jing
    Zhou, Grace Guoying
    MOLECULAR THERAPY ONCOLOGY, 2024, 32 (02):
  • [34] Cell-generated IL12 combined with PD-1 inhibition produces local and abscopal immune activation to eradicate metastatic melanoma and pancreatic cancer
    Nash, Amanda
    Castillo, Bertha
    Murungi, Danna
    Reticker-Flynn, Nathan
    Veiseh, Omid
    CANCER RESEARCH, 2023, 83 (08)
  • [35] Detection of temozolomide-induced hypermutation and response to PD-1 checkpoint inhibitor in recurrent glioblastoma
    Daniel, Paul
    Meehan, Brian
    Sabri, Siham
    Jamali, Fatemeh
    Sarkaria, Jann N.
    Choi, Dongsic
    Garnier, Delphine
    Kitange, Gaspar
    Glennon, Kate, I
    Paccard, Antoine
    Karamchandani, Jason
    Riazalhosseini, Yasser
    Rak, Janusz
    Abdulkarim, Bassam
    NEURO-ONCOLOGY ADVANCES, 2022, 4 (01)
  • [36] PD-1 inhibition enters the frontline
    David Killock
    Nature Reviews Clinical Oncology, 2020, 17 : 69 - 69
  • [37] PD-1 inhibition enters the frontline
    Killock, David
    NATURE REVIEWS CLINICAL ONCOLOGY, 2020, 17 (02) : 69 - 69
  • [38] Combined inhibition of CXCL12 and PD-1 in MSS colorectal and pancreatic cancer: modulation of the microenvironment and clinical effects
    Suarez-Carmona, Meggy
    Williams, Anja
    Schreiber, Jutta
    Hohmann, Nicolas
    Pruefer, Ulrike
    Krauss, Juergen
    Jaeger, Dirk
    Froemming, Anna
    Beyer, Diana
    Eulberg, Dirk
    Jungelius, Jarf Ulf
    Baumann, Matthias
    Mangasarian, Aram
    Halama, Niels
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (10)
  • [39] REGULATING IL-12:IL-23 BALANCE AFFECTS IMMUNOSUPPRESSIVE BEHAVIOR IN GLIOBLASTOMA
    Birks, Suzanne M.
    Burnet, Michael
    Pilkington, Geoff J.
    NEURO-ONCOLOGY, 2011, 13 : 35 - 35
  • [40] PHASE I CLINICAL TRIAL ON SYSTEMIC PD-1 BLOCKADE IN COMBINATION WITH DIRECT INTRA-TUMORAL INJECTION OF CTLA-4/PD-1 IMMUNE CHECKPOINT INHIBITION FOLLOWING RESECTION OF RECURRENT GLIOBLASTOMA
    Duerinck, Johnny
    Du Four, Stephanie
    Ben Salama, Lailia
    De Cremer, Jennifer
    Van Binst, Anne
    Everaert, Hendrik
    Theuns, Pieter
    Rogiers, Anne
    Neyns, Bart
    NEURO-ONCOLOGY, 2017, 19 : 267 - 267
12345